

CMEA VENTURES LIFE SCIENCES 2000 LP
 Form 4
 April 29, 2010

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 CMEA VENTURES LIFE SCIENCES 2000 LP

(Last) (First) (Middle)

ONE EMBARCADERO CENTER, SUITE 3250

(Street)

SAN FRANCISCO, CA 94111

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
 CODEXIS INC [CDXS]

3. Date of Earliest Transaction (Month/Day/Year)
 04/27/2010

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___X___ 10% Owner
 ___ Officer (give title below) ___ Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
 ___X___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|---|-------------------------|
| | | | Code | V | Amount | (A) or (D) | Price | | |
| Common Stock | 04/27/2010 | | C | | 93,727 ⁽¹⁾ <u>(2)</u> | A | <u>(2)</u> 93,727 | I | See Footnote <u>(3)</u> |
| Common Stock | 04/27/2010 | | C | | 62,815 ⁽¹⁾ <u>(4)</u> | A | <u>(4)</u> 156,542 | I | See Footnote <u>(3)</u> |
| Common Stock | 04/27/2010 | | C | | 24,525 ⁽¹⁾ <u>(5)</u> | A | <u>(5)</u> 181,067 | I | See Footnote <u>(3)</u> |
| Common Stock | 04/27/2010 | | C | | 1,418,477 <u>(1) (2)</u> | A | <u>(2)</u> 1,418,477 | I | See Footnote |

| | | | | | | | | |
|--------------|------------|---|----------------------------------|---|------------|-----------|---|---------------------------------------|
| Common Stock | 04/27/2010 | C | 950,638 <u>(1)</u> <u>(4)</u> | A | <u>(4)</u> | 2,369,115 | I | <u>(6)</u> See Footnote <u>(6)</u> |
| Common Stock | 04/27/2010 | C | 371,043 <u>(1)</u> <u>(5)</u> | A | <u>(5)</u> | 2,740,158 | I | <u>(6)</u> See Footnote <u>(6)</u> |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | | |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------|--------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount |
| Series B Preferred Stock | <u>(2)</u> | 04/27/2010 | | C | V (A) 93,727 <u>(1)</u> <u>(2)</u> | <u>(2)</u> <u>(7)</u> | Common Stock | 9 | |
| Series D Preferred Stock | <u>(4)</u> | 04/27/2010 | | C | (D) 62,815 <u>(1)</u> <u>(4)</u> | <u>(4)</u> <u>(7)</u> | Common Stock | 6 | |
| Series E Preferred Stock | <u>(5)</u> | 04/27/2010 | | C | (D) 24,525 <u>(1)</u> <u>(5)</u> | <u>(5)</u> <u>(7)</u> | Common Stock | 2 | |
| Series B Preferred Stock | <u>(2)</u> | 04/27/2010 | | C | (D) 1,418,477 <u>(1)</u> <u>(2)</u> | <u>(2)</u> <u>(7)</u> | Common Stock | 1 | |
| Series D Preferred Stock | <u>(4)</u> | 04/27/2010 | | C | (D) 950,638 <u>(1)</u> <u>(4)</u> | <u>(4)</u> <u>(7)</u> | Common Stock | 9 | |
| Series E Preferred Stock | <u>(5)</u> | 04/27/2010 | | C | (D) 371,043 <u>(1)</u> <u>(5)</u> | <u>(5)</u> <u>(7)</u> | Common Stock | 3 | |
| Warrant to Purchase | \$ 5.96 <u>(1)</u> <u>(8)</u> | 04/27/2010 | | J | (D) 5,730 <u>(1)</u> <u>(8)</u> | <u>(9)</u> 05/25/2013 | Series D Preferred Stock | 5 | |

Series D Preferred Stock

Warrant to Purchase Common Stock

\$ 5.96 ⁽¹⁾/₍₈₎ 04/27/2010 J 5,730 ⁽¹⁾/₍₈₎ ⁽⁹⁾ 05/25/2013 Common Stock

Warrant to Purchase Series D Preferred Stock

\$ 5.96 ⁽¹⁾/₍₈₎ 04/27/2010 J 86,718 ⁽¹⁾/₍₈₎ ⁽⁹⁾ 05/25/2013 Series D Preferred Stock

Warrant to Purchase Common Stock

\$ 5.96 ⁽¹⁾/₍₈₎ 04/27/2010 J 86,718 ⁽¹⁾/₍₈₎ ⁽⁹⁾ 05/25/2013 Common Stock

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| CMEA VENTURES LIFE SCIENCES 2000 LP ONE EMBARCADERO CENTER, SUITE 3250 SAN FRANCISCO, CA 94111 | | X | | |
| CMEA Ventures Life Sciences 2000, Civil Law Partnership ONE EMBARCADERO CENTER, SUITE 3250 SAN FRANCISCO, CA 94111 | | X | | |
| CMEA Ventures LS Management 2000, L.P. ONE EMBARCADERO CENTER, SUITE 3250 SAN FRANCISCO, CA 94111 | | X | | |
| Collier David J ONE EMBARCADERO CENTER, SUITE 3250 SAN FRANCISCO, CA 94111 | | X | | |
| Handelsman Karl D. ONE EMBARCADERO CENTER, SUITE 3250 SAN FRANCISCO, CA 94111 | | X | | |

Signatures

/s/ Thomas R. Baruch, General Partner of CMEA Ventures LS Management 2000, L.P. for CMEA Ventures Life Sciences 2000, L.P. as its General Partner

04/29/2010

**Signature of Reporting Person

Date

Edgar Filing: CMEA VENTURES LIFE SCIENCES 2000 LP - Form 4

| | |
|---|------------|
| /s/ Thomas R. Baruch, General Partner of CMEA Ventures LS Management 2000, L.P. for CMEA Ventures Life Sciences 2000, Civil Law Partnership as its managing limited partner | 04/29/2010 |
| __Signature of Reporting Person | Date |
| /s/ Thomas R. Baruch, General Partner of CMEA Ventures LS Management 2000, L.P. | 04/29/2010 |
| __Signature of Reporting Person | Date |
| /s/ David Collier | 04/29/2010 |
| __Signature of Reporting Person | Date |
| /s/ Karl Handelsman | 04/29/2010 |
| __Signature of Reporting Person | Date |

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects a 2-for-3 reverse stock split of the Issuer's outstanding securities effected immediately prior to the effectiveness of the Issuer's S-1 Registration Statement (Commission File No. 333-164044).
 - (2) Each share of Series B Preferred Stock automatically converted into Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

Held by CMEA Ventures Life Sciences 2000, Civil Law Partnership. Thomas R. Baruch, a member of the Issuer's board of directors, David Collier and Karl Handelsman are general partners of CMEA Ventures LS Management 2000, L.P., the managing limited partner of
 - (3) CMEA Ventures Life Sciences 2000, Civil Law Partnership, and, as such, have voting and investment power over the securities held by CMEA Ventures Life Sciences 2000, Civil Law Partnership. Each of the Reporting Persons disclaims beneficial ownership of the securities reported in this Form 4 except to the extent of any pecuniary interest therein.
 - (4) Each share of Series D Preferred Stock automatically converted into Common Stock on a 1-for-1 basis upon the closing of the Issuer's initial public offering.

As previously reported on the Form 3 dated April 21, 2010, due to the antidilution provisions of the Issuer's certificate of incorporation that apply to the Series E Preferred Stock, each share of Series E Preferred Stock automatically converted into Common Stock on a
 - (5) 1.008702-for-1 basis upon the closing of the Issuer's initial public offering. Number of shares reported includes the additional 211 shares and 3,200 shares of Common Stock that was issued to CMEA Ventures Life Sciences 2000, Civil Law Partnership and CMEA Ventures Life Sciences 2000, L.P., respectively, upon such conversion as a result of such antidilution adjustment.

Held by CMEA Ventures Life Sciences 2000, L.P. Thomas R. Baruch, a member of the Issuer's board of directors, David Collier and Karl Handelsman are general partners of CMEA Ventures LS Management 2000, L.P., the general partner of CMEA Ventures Life Sciences
 - (6) 2000, L.P., and, as such, have voting and investment power over the securities held by CMEA Ventures Life Sciences 2000, L.P. Each of the Reporting Persons disclaims beneficial ownership of the securities reported in this Form 4 except to the extent of any pecuniary interest therein.
 - (7) The expiration date is not relevant to the conversion of these securities.

Upon completion of the Issuer's initial public offering, the warrant to purchase shares of Series D Preferred Stock automatically converted
 - (8) into a warrant to purchase an equal number of shares of the Issuer's Common Stock. Disposition of Warrant to Series D Preferred Stock and acquisition of Warrant to Purchase Common Stock listed solely for the purpose of reporting such conversion of the shares underlying the security.
 - (9) This warrant is immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.